{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:09Z","timestamp":1781179089270,"version":"3.54.1"},"reference-count":39,"publisher":"Scientific Scholar","issue":"01","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Background\u2003Systemic fluoropyrimidines, both oral and intravenous, are an integral part of colorectal cancer (CRC) management. They can be administered either with curative or palliative intent.<\/jats:p>\n                  <jats:p>Objectives\u2003This article examines the literature to analyze the efficacy and safety of the oral fixed-dose combination of uracil and tegafur (UFT)\/leucovorin (LV) compared with other fluoropyrimidine agents, with an intention to implement the findings into the current treatment algorithms for CRC.<\/jats:p>\n                  <jats:p>Methods\u2003An exhaustive systematic literature search was performed for prospective studies using PUBMED, Cochrane Library, and EMBASE database. Studies which met eligibility criteria were shortlisted and grouped into chemotherapy given for curative or palliative intent.<\/jats:p>\n                  <jats:p>Results\u2003Eight trials were shortlisted involving 4,486 patients for the analysis. There was no difference between UFT\/LV and other fluoropyrimidines in the primary endpoints\u2014disease-free survival (hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.90\u2013.15; p\u2009=\u20090.81) and progression-free survival (HR 0.87; 95% CI 0.66\u2013.66; p\u2009=\u20090.35) for curative and palliative intent CRC patients, respectively. In secondary analyses, there was no significant difference observed between UFT and other fluoropyrimidines in overall survival in CRC patients with curative intent (HR 1.04; 95% CI 0.88\u20131.23; p\u2009=\u20090.63) and palliative intent (HR 1.02; 95% CI 0.97\u20131.06; p\u2009=\u20090.42) . In the safety analysis, we found significantly lesser patients on UFT\/LV had stomatitis\/mucositis (odds ratio [OR] 0.20; 95% CI 0.05\u20130.85; p\u2009=\u20090.03), fever (OR 0.46; 95% CI 0.29\u20130.71; p\u2009&lt;\u20090.001), infection (OR 0.42; 95% CI 0.24\u20130.74; p\u2009&lt;\u20090.01), leukopenia (OR 0.04; 95% CI 0.00\u20130.95; p\u2009=\u20090.05), febrile neutropenia (OR 0.03; 95% CI 0.00\u20130.24; p\u2009=\u20090.001), and thrombocytopenia (OR 0.14; 95% CI 0.02\u20130.79; p\u2009=\u20090.03) compared with other fluoropyrimidines.<\/jats:p>\n                  <jats:p>Conclusion\u2003Oral UFT\/LV is equally efficacious to other fluoropyrimidines, especially intravenous 5-fluorouracil, in the management of early as well as advanced CRC patients. Importantly, UFT\/LV has a superior safety profile compared with other fluoropyrimidines in terms of both hematological and nonhematological adverse events.<\/jats:p>","DOI":"10.1055\/s-0041-1735650","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T18:56:38Z","timestamp":1643828198000},"page":"084-094","source":"Crossref","is-referenced-by-count":5,"title":["Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.25259","volume":"11","author":[{"given":"Satya Pal","family":"Kataria","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Nagar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lupin Ltd., Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Purohit","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lupin Ltd., Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"ref1","volume-title":"Global Cancer Observatory: Cancer Today","author":"J Ferlay","year":"2018"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.30766","article-title":"Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years","volume":"141","author":"P Snaebjornsson","year":"2017","journal-title":"Int J Cancer"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1533-0028(11)70502-3","article-title":"Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation","volume":"2","author":"R L Schilsky","year":"2002","journal-title":"Clin Colorectal Cancer"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0277-5379(82)90215-2","article-title":"The enhancement of 5-fluorouracil anti-metabolic activity by leucovorin, menadione and alpha-tocopherol","volume":"18","author":"S Waxman","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"S 01","key":"ref8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1120009X.1990.11738998","article-title":"Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience","volume":"2","author":"Y M Rustum","year":"1990","journal-title":"J Chemother"},{"issue":"10","key":"ref9","first-page":"1803","article-title":"Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study","volume":"66","author":"D Machover","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006445214741","article-title":"The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT\/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential","volume":"18","author":"P M Hoff","year":"2000","journal-title":"Invest New Drugs"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"G Liu","year":"1997","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/annonc\/mdj023","article-title":"A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil\/leucovorin regimens in patients with advanced colorectal cancer","volume":"17","author":"C Twelves","year":"2006","journal-title":"Ann Oncol"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jjco\/hyl014","article-title":"Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial","volume":"36","author":"T Akasu","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1463-1318.2009.02184.x","article-title":"Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials","volume":"13","author":"Q Bin","year":"2011","journal-title":"Colorectal Dis"},{"issue":"07","key":"ref16","first-page":"CD008398","article-title":"Oral versus intravenous fluoropyrimidines for colorectal cancer","volume":"7","author":"F Chionh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ejca.2014.05.025","article-title":"Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2\/D3 lymph node dissection: final results of JCOG0205","volume":"50","author":"Y Shimada","year":"2014","journal-title":"Eur J Cancer"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jgo.2015.05.004","article-title":"Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer\u2013TLC study","volume":"6","author":"J R Kroep","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"30","key":"ref19","doi-asserted-by":"crossref","first-page":"e16667","DOI":"10.1097\/MD.0000000000016667","article-title":"Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: a systematic review and meta-analysis","volume":"98","author":"J Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"D Moher","year":"2010","journal-title":"Int J Surg"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J PT Higgins","year":"2019","edition":"2nd ed."},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"A Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"E A Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"M M Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"J P Higgins","year":"2011","journal-title":"BMJ"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"A R Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3349\/ymj.2003.44.4.665","article-title":"Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer","volume":"44","author":"D J Kim","year":"2003","journal-title":"Yonsei Med J"},{"issue":"13","key":"ref28","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2005.04.7498","article-title":"Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06","volume":"24","author":"B C Lembersky","year":"2006","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2007.05.068","article-title":"Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin","volume":"70","author":"A de la Torre","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"J Y Douillard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref31","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","article-title":"Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"J Carmichael","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref32","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ejca.2005.07.013","article-title":"Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer","volume":"41","author":"M Nogu\u00e9","year":"2005","journal-title":"Eur J Cancer"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0039-6109(16)42587-9","article-title":"Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial","volume":"61","author":"T B Grage","year":"1981","journal-title":"Surg Clin North Am"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","author":"R Gray","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"J F Bosset","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"K Bujko","year":"2006","journal-title":"Br J Surg"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.1992.10.6.904","article-title":"Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial","volume":"10","author":"Nordic Gastrointestinal Tumor Adjuvant Therapy Group","year":"1992","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.12.010","article-title":"A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients","volume":"122","author":"C Baratelli","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"D Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1524-4733.2002.51083.x","article-title":"The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer","volume":"5","author":"T E Delea","year":"2002","journal-title":"Value Health"},{"issue":"08","key":"ref41","first-page":"2185","article-title":"UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice","volume":"5","author":"K Yonekura","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"02","key":"ref42","first-page":"31","article-title":"Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells","volume":"6","author":"U Testa","year":"2018","journal-title":"Med Sci (Basel)"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1735650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:27Z","timestamp":1781176347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/oral-tegafur-uracil-combination-plus-leucovorin-versus-other-fluoropyrimidine-agents-in-colorectal-cancer-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,7,11]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1735650","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}